Drug
Kx2 391 1
Kx2 391 1: highest development phase Phase 3, developed by Almirall, Athenex. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Almirall, Athenex
Trials
| Drug | Phase | Indication |
|---|---|---|
| KX2-391 Ointment 1% NCT03285477 | Phase 3 | Actinic Keratoses |
| KX2-391 Ointment 1% NCT03285490 | Phase 3 | Actinic Keratosis |
| KX2-391 Ointment 1% NCT03575780 | Phase 1 | Actinic Keratoses |
Latest
No recent events.
Follow Kx2 391 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.